UP’s Pharma Investment Tally Crosses ₹38,000 Crore as State Bets Big on Manufacturing
Bulk Drug Park, Medical Device Hub, and fresh conclave deals position Uttar Pradesh as a rising pharma powerhouse
Uttar Pradesh has attracted over ₹38,000 crore in pharmaceutical investment proposals, sharpening its pitch as India’s next major pharma hub.
The state logged 210 proposals worth ₹28,000 crore after the 2024 Global Investors’ Summit. A recent UP Pharma Conclave in Lucknow added about a dozen fresh commitments, pushing the total higher.
Big-Ticket Commitments Roll In
Among the key investment pledges:
- ₹1,250 crore each from Arna Pharma and Biogenta Lifesciences
- ₹737 crore from Shukra Pharmaceuticals
- ₹590 crore from Walter Bushnell Enterprises
- ₹553 crore from Jhanvika Labs
A senior official said the investments will foster innovation and expand healthcare manufacturing capacity in the state.
For context, India’s pharma market is projected to reach $120 billion by 2030, and Uttar Pradesh already accounts for roughly 17% of domestic sales.
Infrastructure to Anchor Growth
The state is backing the capital inflow with industrial infrastructure.
Projects underway include:
- A 2,000-acre Bulk Drug Pharma Park in Lalitpur
- A 350-acre Medical Device Park near the upcoming Noida International Airport in the NCR
The Yamuna Expressway Industrial Development Authority (YEIDA) is also building flatted factories for medical devices, aimed at lowering entry barriers for manufacturers.
The strategy resembles building an airport before launching an airline—capacity first, traffic later.
Industry Heavyweights Show Up
The conclave drew top pharma executives, including:
- Dilip Shanghvi (Sun Pharma)
- Pankaj R. Patel (Zydus Lifesciences)
- Ramesh Juneja (Mankind Pharma)
- Satish Reddy (Dr. Reddy’s Laboratories)
- Jinal Mehta (Torrent Group)
Chief Minister Yogi Adityanath said the projects reflect the state’s intent to build a “strong end-to-end pharmaceutical ecosystem.”
Tapping a Global Opportunity
India ranks among the top three countries globally by medicine volume and commands a 20% share of the global generic medicines market by volume.
Yet in medical devices, the country imports nearly 80% of its requirements, particularly high-end equipment such as cancer diagnostics, imaging systems, and ultrasonic scanners.
The UP push aims to change that equation.
Planned manufacturing includes:
- Orthopedic and spinal implants
- Oxygen concentrators and ICU ventilators
- Anaesthesia kits and ECG machines
- X-ray machines and chemotherapy devices
- Portable mobile labs
The goal is not only to serve domestic demand but also to tap export markets.
Can Uttar Pradesh convert investment intent into sustained production scale? Execution will decide whether this becomes a headline—or a long-term industrial shift.
TL;DR:
Uttar Pradesh has secured over ₹38,000 crore in pharma investment proposals, backed by a 2,000-acre Bulk Drug Park and a Medical Device Park near Noida Airport. With India’s pharma market heading toward $120 billion by 2030, UP aims to become a manufacturing and export hub.
AI summary:
- ₹38,000 crore pharma investment proposals in UP.
- 210 proposals post-2024 GIS plus fresh conclave deals.
- Bulk Drug Park and Medical Device Park underway.
- India imports 80% of medical devices.
- UP targets domestic and export markets.
